FMXIN002 single dose

Small molecule

NNasus Pharma

FMXIN002 single dose is one of 28 small molecule programs targeting Allergic Rhinitis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic RhinitisActive, not recruiting

Allergic RhinitisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

271 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

Sudafed

KKenvue Brands

Phase 3

3 2

Asmanex HFA

Sumitomo Pharma America, Inc.

Phase 3

1 3

Ciclesonide HFA

Sumitomo Pharma America, Inc.

Phase 3

3 4

EMS Acarbose

EEMS

Phase 3

2 5

Asmanex

Novartis

Preclinical

12 6

HL151

HHanlim Pharm. Co., Ltd.

Phase 3

1 7

Veramyst

GSK

Preclinical

10 8

Singulair

AstraZeneca

Preclinical

5 9

Xolair

Roche

Preclinical

1 10

Bilaxten

MMenarini International Operations Luxembourg SA

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Allergic Rhinitis1 trial

Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis

Enrolling by invitation·NNasus Pharma·Phase 1/2·NCT07228325·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for FMXIN002 single dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FMXIN002 single dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FMXIN002 single dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nasus Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: NNasus Pharma

FMXIN002 single dose

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Allergic Rhinitis1 trial

References

Drug Info

Quick Facts

Related News